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Recommended by Shahid Jameel
Whilst BCG inhibits allergic airway responses in murine models, IL-18 has adversary eﬀects depending on its environment. We
therefore constructed a BCG strain producing murine IL-18 (BCG-IL-18) and evaluated its eﬃciency to prevent an asthma-like
reaction in mice. BALB/cByJ mice were sensitized (day (D) 1 and D10) by intraperitoneal injection of ovalbumin (OVA)-alum and
primary(D20–22)andsecondary(D62,63)challengedwithOVAaerosols.BCGorBCG-IL-18wereintraperitonealyadministered
1 hour before each immunization (D1 and D10). BCG-IL-18 and BCG were shown to similarly inhibit the development of AHR,
mucus production, eosinophil inﬂux, and local Th2 cytokine production in BAL, both after the primary and secondary challenge.
These data show that IL-18 did not increase allergic airway responses in the context of the mycobacterial infection, and suggest
thatBCG-IL-18andBCGareabletopreventthedevelopmentoflocalTh2responsesandthereforeinhibitallergen-inducedairway
responses even after restimulation.
Copyright © 2007 L. Amniai et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Airway inﬂammation and hyperresponsiveness, increased
Th2 cytokine production in bronchoalveolar lavage, and en-
hanced IgE secretion in serum are the hallmarks of aller-
gic asthma. Increased prevalence of asthma has been re-
lated to decreased microbial infection or immunization dur-
ing early infancy. In particular, Mycobacterium bovis Bacil-
lus Calmette-Guerin (BCG) vaccination have been suggested
to decrease the risk of asthma in a population with family
history of rhinitis or eczema [1, 2]. Studies in mouse mod-
els have shown that BCG immunization inhibits the devel-
opment of asthma features in ovalbumin (OVA)-sensitized
mice [3–8]. Several authors reported a switch toward a Th1
pattern of response [3, 5, 9], with little evidence of increased
regulatory cellactivity, since production of the regulatorycy-
tokine IL-10 as well as production of IL-4 was suppressed
[3, 9].
Originally named IFN-γ-inducing factor, IL-18 is impor-
tant for the generation of protective immunity to mycobac-
teria. IL-18-deﬁcient mice infected with Mycobacterium tu-
berculosisandMycobacteriumbovisBCGdevelopedincreased
granulomatous lesions while IFN-γ production decreased
[10]. IL-18 role on allergic inﬂammation is complex, as
it can promote both Th1 and Th2 responses depending
on its environment, the time of its administration and/or
the response assessment. IL-18 deﬁciency selectively en-
hances OVA-induced eosinophilia in mice, whereas IL-18
gene transfer by adenovirus into the respiratory tract at the
time of OVA airway challenge prevents the development of
airway hyperresponsiveness (AHR) and decreases allergen-
speciﬁc IL-4 production, airway eosinophilia, mucus pro-
duction, and increases IFN-γ production [11, 12]. In con-
trast, high doses of IL-18 administered alone or concomi-
tantly with the antigen have been shown to increase allergic
sensitization including serum IgE, Th2 cytokines and airway2 Journal of Biomedicine and Biotechnology
eosinophilia, especially 3 weeks afterIL-18 injection [13]. In-
traperitoneal coadministration of IL-18 and IL-12 or IL-18
and IL-2 during the airway challenge period inhibits AHR,
eosinophilia, and serum IgE levels [14, 15], whilst intranasal
of IL-18 plus IL-2 induced allergic airway disease in na¨ ıve
mice [16].
A BCG producing IL-18 was shown to exhibit enhanced
antimicrobial immunity compared to nonrecombinant BCG
due to increased production of IFN-γ [17]. Therefore, we
constructed a recombinant BCG producing IL-18 (BCG-IL-
18) in order to increase the eﬃciency of intraperitoneally in-
jected BCG in preventing allergic reactions. This strain pro-
duceslowdosesofIL-18andincreasesTh1response[18].We
previously showed that intraperitoneal (i.p.) BCG-IL-18 im-
munization at the time of OVA sensitization decreases bron-
choalveolar lavage (BAL) eosinophilia, IL-5 production by
lymph node cells, but increases IFN-γ production by lymph
node cells [19]. The aim of the present work was ﬁrstly to
evaluate the eﬀect of nonrecombinant BCG and BCG-IL-18
immunization on AHR, and secondly to analyze BCG and
BCG-IL-18 eﬀects in the long term, that is, after a secondary
challenge occurring 6 weeks after the primary OVA chal-
lenge. We showed that both BCG and BCG-IL-18 were able
to similarly prevent AHR and airway inﬂammation (BAL
eosinophilia, Th2 cytokine production in BAL, and mucus
production) after primary and secondary challenges.
2. MATERIALS AND METHODS
2.1. Sensitizationandairwaychallengefor
acuteandchronicinﬂammatoryreaction
10–12-week-old female BALB/c mice (H-2d)( I ﬀaC r e d o ,
l’Arbresle, France) were sensitized by i.p. injection of 20μg
ovalbumin (OVA) (Grade V, Sigma Chemical Co., St. Louis,
M o ,U S A )e m u l s i ﬁ e di n2 . 2 5m ga l u m i n u mh y d r o x i d e( A l u -
mImject: Pierce, Rockford, Ill, USA) in a total volume of
100μL on days (D)1 and 10. Mice were challenged (20 min-
utes)viatheairwayswithOVA(1%insaline)for3days(D20,
21, and 22) using ultrasonic nebulization. Mice were divided
into2groups:thegroupsofOVA-sensitizedmicewerei.p.in-
jected with OVA and received OVA challenges aerosols. The
groups of nonsensitized mice only received OVA challenges
by aerosols.
In the primary challenge protocol, 48 hours after the last
OVA challenge (D24), AHR and tissues were assessed. For
the secondary challenge protocol, 6 weeks after the ﬁrst chal-
lenge, mice were exposed to OVA challenges (1% in saline on
D62, 5% in saline on D63), and airway reactivity and tissues
were assessed on D64. Nonsensitized control groups only re-
ceived OVA challenges by aerosols.
2.2. ImmunizationwithBCGorIL-18-producing
recombinantBCG
Nonsensitized and sensitized mice were or were not treated
with BCG or BCG-IL-18. Mycobacterium bovis BCG (Pasteur
strain 1173P2; WHO Stockholm, Sweden) and the recom-
binant BCG producing IL-18 (BCG-IL-18) [18]w e r eg r o w n ,
usingstationaryﬂasks,at37◦CinSautonmediumcontaining
10μg/mL HgCl2 when required and frozen until use. Non-
recombinant BCG or rBCG producing IL-18 were adminis-
tered intraperitoneally on D0 and D10 (5 × 106 CFU in a
ﬁnal volume of 100μL).
2.3. AirwayHyperresponsivness
Airway responsiveness was assessed using single-chamber-
whole body plethysmography (Buxco Electronics, Sharon,
Conn, USA), as described previously [20]. Enhanced pause
(Penh) was used as the measure of airway responsiveness
in this study. In the plethysmography, mice were exposed
for 2 minutes to nebulized PBS and followed by increas-
ing concentrations of nebulized methacholine (MCh) (1,5–
12mg/mL in PBS) (Sigma-Aldrich) using an Aerosonic ul-
trasonic nebulizer (Systam, Villeneuve sur Lot, France). Af-
ter each nebulization, recordings were taken for 3 minutes.
The Penh values measured during each 3-minute sequence
were averaged and were expressed for each MCh concentra-
tion as the percentage of baseline Penh values was measured
after PBS exposure. There were no signiﬁcant diﬀerences in
any of the treatment groups for baseline(PBS) Penh.
2.4. BronchoalveolarLavage
Immediately after assessment of AHR, lungs were lavaged via
the tracheal tube with PBS (1 × 1mL). Total leukocyte num-
bers were counted with a hemocytometer. Diﬀerential cell
countswereperformedonbronchoalveolarlavagesbycount-
ing at least 200 cells on cytocentrifuged preparations, stained
withDiﬀ Quick (Dade Behring, Deerﬁeld, Ill, USA), and dif-
ferentiated by standard hematological procedures.
2.5. Histochemistry
Lungs were ﬁxed by inﬂation (1mL) and immersion in Im-
munohistoﬁx (Aphase, Gosselies, Belgium) and embedded
in Immunohistowax (Aphase). For detection of mucus con-
taining cells in ﬁxed airway tissue, 5μm sections were stained
with Periodic Acid Schiﬀ (PAS) (Sigma Aldrich) and hema-
toxylin (Labonord, Templemars, France) as previously de-
scribed [21].
2.6. Measurementofcytokines
IFN-γ, IL-5, IL-12, and IL-13 levels in the bronchoalveolar
lavage ﬂuid (BALF) were measured by ELISA according to
the manufacturer direction (Pharmingen, San Diego, Calif,
USA) for IFN-γ, IL-5, IL-12 and (R&D systems, Mineapolis,
Mn, USA) for IL-13. The limits of detection were 4pg/mL
for IL-5, 10pg/mL for IL-12 and IFN-γ,a n d1 . 5p g / m Lf o r
IL-13.
2.7. MeasurementoftotalandOVA-speciﬁcserumIgE
Serum levels of total IgE, and OVA-speciﬁc IgE were mea-
sured by ELISA as previously described [19]. Brieﬂy, 96-well
plates (Immulon 2, Dynatech, Chantilly, Va, USA) wereL. Amniai et al. 3
coatedwitheitherOVA(5μg/mL)orpuriﬁedanti-IgE(clone
02111D, Pharmingen). After addition of serum samples, a
biotinylated anti-IgE antibody (clone 02122D, Pharmingen)
was used as detecting antibody, and the reaction ampliﬁed
with avidin-horseradish peroxidase (Sigma Aldrich). The
OVA-speciﬁc antibody titers of the samples were related to
pooled standards that were generated in the laboratory and
expressed as ELISA units per mL (EU/mL). Total IgE levels
were calculated by comparison with known mouse IgE stan-
dards (Pharmingen). The limit of detection was 100pg/mL
for total IgE.
2.8. Statisticalanalysis
Values for all measurements were expressed as the mean
± standard error of the mean (SEM). Statistical analyses
were done using STATVIEW 5 software. Diﬀerences within
all groups were ﬁrst evaluated for each parameter using the
Kruskal Wallis test. When statistical signiﬁcance was ob-
served, diﬀerences were subsequently analyzed by using the
Mann Whitney test. P values for signiﬁcance were set to .05.
3. RESULTS
3.1. BCGandBCG-IL-18preventedairway
hyperresponsivenessfollowingprimaryand
secondarychallenge
OVA-sensitized mice developed airway hyperresponsive-
ness compared to the nonsensitized mice after primary
(see Figure 1(a)) and secondary (see Figure 1(b)) challenge.
Mouse treatment by intraperitoneal injections with BCG or
IL-18-producing-BCG (BCG-IL-18) before and during sen-
sitization signiﬁcantly inhibited airway hyperresponsiveness
(see Figure 1(a)). In order to evaluate the long-term eﬀect of
BCG and BCG-IL-18 on AHR, we waited 6 weeks after the
primary challenge and then rechallenged the animals. It has
previously been shown that at this time point, the inﬂamma-
tory reaction and AHR developing after primary challenge
are resolved but that a secondary airway challenge induces
a strong inﬂammatory reaction with concomitant develop-
ment of AHR [22]. Under these conditions, BCG and BCG-
IL-18 treatment inhibited the increase in airway reactivity
(see Figure 1(b)). Baseline airway reactivity was not aﬀected
by OVA, BCG or BCG-IL-18 treatment (data not shown).
3.2. BCGandBCG-IL-18decreasedBALinﬂammation
andgobletcellhyperplasiafollowingprimaryand
secondarychallenge
In OVA-sensitized mice, inﬂammatory cell recruitment into
the airways was increased after primary as well as secondary
airway challenge (see Figure 2). Increased total cell numbers
in BAL were largely due to increased numbers of eosinophils.
There was also a small but signiﬁcant (P = .0005) increase
in the number of lymphocytes compared to the nonsensi-
tized mice (see Figure 2). Administration of BCG or BCG-
IL-18 led to a signiﬁcant (P < .05) decrease in total cell num-
bers, macrophage, lymphocyte, and eosinophil numbers, in
the primary challenge protocol compared to OVA-sensitized
mice (see Figure 2(a)). In the secondary challenge protocol,
administration of BCG or BCG-IL-18 signiﬁcantly decreased
eosinophil numbers only (see Figure 2(b)).
Lung tissue was obtained and processed 48 hours af-
ter allergen provocation. To assess the degree of goblet cell
hyperplasia, tissue sections were stained with PAS. After
primary (see Figures 3(a)–3(d)) and secondary (see Fig-
ures 3(e)–3(h)) challenge, nonsensitized mice showed no
PAS-positive cells, whereas nontreated OVA-sensitized mice
showed many PAS-positive cells (92% and 81% of PAS pos-
itive cells/mm basement membrane for the primary and
secondary challenge protocol, resp.). In contrast, sensitized
and BCG- or BCG-IL-18-treated mice showed only scattered
PAS-positive cells (71% and 66% of PAS-positive cells/mm
basement membrane for BCG-treated mice in the primary
and secondary challenge protocol, resp., and 48% and 40%
of PAS-positive cells/mm basement membrane for BCG-IL-
18-treated mice in the primary and secondary challenge pro-
tocol, resp.), with a stronger inhibition for BCG-IL-18 treat-
ment after the secondary challenge (Figure 3(h)).
3.3. EffectofBCGandBCG-IL-18on
cytokineproductionfollowingprimaryand
secondarychallenges
BAL ﬂuid was obtained in order to assess Th1 (IFN-γ), pro-
Th1 (IL-12), and Th2 (IL-5, IL-13) cytokine levels, 48 or 24
hours after primary or secondary allergen challenge, respec-
tively. Th1 (IFN-γ) and pro-Th1 (IL-12) cytokines were de-
creased in OVA-sensitized mice compared to nonsensitized
mice, signiﬁcantly after the primary challenge, and non-
signiﬁcantly after the secondary challenge (see Figure 4). IL-
5 and IL-13 production was signiﬁcantly increased in OVA-
sensitized mice after the primary and the secondary chal-
lenge. Treatment of OVA-sensitized mice with BCG or BCG-
IL-18 did not signiﬁcantly aﬀect IFN-γ,I L - 1 2( s e eFigure 4)
or IL-10 (data not shown) production, but signiﬁcantly in-
h i b i t e dI L - 5a n dI L - 1 3p r o d u c t i o nb o t hi np r i m a r ya n ds e c -
ondary challenge protocols.
3.4. BCGandBCG-IL-18treatmentdidnotmodifytotal
IgEproductionbutinhibitedOVA-speciﬁcIgE
Serum from OVA-sensitized mice showed elevated total IgE
levels and OVA-speciﬁc IgE antibodies compared to nonsen-
sitized mice following the primary and the secondary chal-
lengeprotocol(seeFigure 5).TreatmentwithBCGandBCG-
IL-18 did not aﬀect total IgE measured after the primary and
the secondary challenge (see Figures 5(a) and 5(b)). OVA-
speciﬁc IgE measured after the primary or the secondary
challenge were not modiﬁed after BCG treatment (see Fig-
ures 5(c) and 5(d)). In contrast, treatment with BCG-IL-
18 signiﬁcantly increased levels of OVA-speciﬁc IgE after the
primary and decreased them after the secondary challenge
compared to OVA-sensitized mice (see Figures 5(c), 5(d)).4 Journal of Biomedicine and Biotechnology
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Figure 1: BCG and BCG-IL-18 prevent the development of AHR. OVA-sensitized mice were OVA-sensitized and challenged, whereas non-
sensitized mice were challenged only. At the time of each OVA sensitization, treated mice were injected either with BCG or BCG-IL-18.
Airway reactivity was evaluated after inhalation of increasing doses of metacholine by whole body plethysmography and penh (enhanced
pause) measurement after primary (a) or secondary (b) challenge. Results are expressed as mean ± SEM of penh percentage increase above
PBS inhalation. Statistical analysis was performed and showed P < .04 for diﬀerences between OVA-challenged and OVA-sensitized and chal-
lenged mice (1), between OVA-sensitized and challenged mice and OVA-sensitized and challenged mice + BCG treatment (2), and between
OVA-sensitized and challenged mice and OVA-sensitized and challenged mice + BCG-IL-18 treatment (3).
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Figure 2: BCG and BCG-IL-18 eﬀect on BAL composition after primary and secondary challenge. BAL inﬁltrate was analyzed after primary
(a) or secondary (b) challenge. Results are expressed as mean ± sem of cell number. ∗ P < .05.L. Amniai et al. 5
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Figure 3: BCG and BCG-IL-18 eﬀect on mucus hyperplasia after primary and secondary challenge. Mucus production was detected using
Periodic Acid Schiﬀ staining on lung section from nonsensitized mice (a), (e), sensitized mice (b), (f), sensitized mice treated with BCG (c),
(g), or BCG-IL-18 (d), (h), after primary (a)–(d) or secondary (e)–(h) OVA challenge.
4. DISCUSSION
In this study we showed that BCG and BCG-IL-18 given at
the time of OVA sensitization were eﬃcient to prevent AHR
even after a secondary challenge performed 6 weeks after the
initial allergen challenge. This eﬀect is related to the decrease
inthelocalTh2immuneresponse,asseenwiththedecreased
BAL IL-5 and IL-13 production. In human as well as in
mouse models, Th2 cells are indeed considered as the central
cells involved in the development of asthma [23, 24]. Oth-
ers have shown that BCG was eﬀective in attenuating allergic
airway inﬂammation and associated changes in pulmonary
function in animal models. Administered before OVA sensi-
tization, BCG decreases BAL eosinophilia and IL-5 produc-
tion in the draining lymph nodes in an IFN-γ-dependent
manner [4]. In our hands, in a previous study, similar eﬀects
were found both with intraperitoneal and intranasal admin-
istration at the dose of 5 × 106 CFU, when BCG was given
at the time of OVA sensitization [19]. Systemically injected
(by intravenous injection) 14 days before the challenge, BCG
also suppressed OVA-induced airway responses [9]. In the
present study, BCG was injected i.p. at the time of sensitiza-
tion, and inhibition of airway responses was still observed 10
weeks after the ﬁrst injection. Only few studies investigated
BCG long-term eﬀects: similar results to ours were obtained
although BCG was always given long before OVA sensitiza-
tion. Given from 4 to 16 weeks before OVA sensitization by
i.n.immunization,BCGpreventedairwayallergicinﬂamma-
tion [7, 8].
After primary and secondary challenge, BCG and BCG-
IL-18 treatment locally decreased the production of IL-5 and
IL-13,inparalleltodecreasedmucushyperplasia,arguingfor
a role, in this process, of IL-13, the main cytokine involved
in mucus production [25, 26]. However, BCG treatment did
not modify IFN-γ and IL-12 production in BAL, in contrast
to decreased IFN-γ production seen in the spleen [9] or the6 Journal of Biomedicine and Biotechnology
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Figure 4: BCG and BCG-IL-18 eﬀect on BAL cytokine production after primary and secondary challenge. BAL cytokines were measured
after primary (a) or secondary (b) challenge. Results are expressed as mean ± sem pg/mL. ∗ P < .03.
draining lymph nodes [19]. This absence of eﬀect on IFN-γ
production in BAL may be due to the way of injection (i.p.
instead i.n. route of administration) and the analyzed tissue.
Another hypothesis, pointed out by Trujillo and colleagues
[27] suggests that the treatment before sensitization may in-
hibit the onset and consequently the recruitment of Th2 cells
thus preventing from allergic reaction. Our previous stud-
ies are in favor of this hypothesis as we showed that i.p.L. Amniai et al. 7
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Figure 5: BCG and BCG-IL-18 decrease OVA-speciﬁc IgE, but do not modify serum total IgE. IgE were measured after primary (a), (c) or
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administration of BCG or BCG-IL-18 increased in vitro pro-
duction of IFN-γ by splenocytes or lymph node cells, whilst
decreasing IL-5 production [18, 19].
In the present work, total IgE production was unchanged
after BCG treatment either following primary or secondary
challenge, suggesting that BCG was not able to totally pre-
vent Th2 responses. Although Mycobacterium tuberculosis
has been shown to induce IgE production [28], BCG was
showntopreventOVA-speciﬁcIgEproductionaftersystemic
(intravenous), but not local (i.n.) administration [4, 7, 9]. In
our study, BCG does not seem to induce total IgE either as
nonsensitized mice treated with BCG-IL-18 did not develop
total IgE response, either in the primary or the secondary
challengeprotocol.However,BCGandBCG-IL-18treatment
decreased OVA-speciﬁc IgE after the secondary challenge, as
well as OVA-speciﬁc IgG1 (data not shown). Only BCG-IL-
18 treatment eﬀect was signiﬁcant suggesting a potentiating
eﬀect of IL-18 produced by BCG and a long-term eﬀect of
BCG-IL-18.
However, BCG-IL-18 did not demonstrate a stronger
ability to prevent airway inﬂammation and hyperrespon-
siveness than BCG alone, in contrast to what we previously
showed [19]. The protocol used to sensitize mice in this
ﬁrst study was much weaker (sensitizing doses were twice
lesser and OVA aerosol concentration were 0.1% OVA in-
stead of 1% in the present study) and did not allow the mea-
surement of signiﬁcant AHR. The absence of a diﬀerential
eﬀect between BCG and BCG-IL-18 may therefore be re-
lated to the strength of the sensitization protocol and the al-
ready maximal eﬀect of the nonrecombinant BCG on AHR.8 Journal of Biomedicine and Biotechnology
We previously showed that BCG and BCG-IL-18 were still
viable and detected after 94 days. Moreover, although unde-
tectable, IL-18 was eﬃciently produced in vivo by the recom-
binant BGC, as suggested by its potentiating eﬀect over non-
recombinant BCG [18, 19]. In the present study, BCG-IL-18
signiﬁcantly modiﬁed OVA-speciﬁc IgE production in con-
trast to nonrecombinant BCG, suggesting that IL-18 is really
produced in vivo, probably in low concentration.
Finally, after the primary and secondary OVA challenge,
BCG or BCG-IL-18 treatment inhibits BAL eosinophilia.
BCG was already known to inhibit this feature of asthma
when given before sensitization [7]. Interestingly BCG-IL-
18 increased the number of BAL lymphocytes compared to
BCG-treated mice and BCG-nontreated mice. This was not
accompanied with decreased or increased airway responses,
in contrast to the increased Th2 response induced by IL-18
as previously shown [13]. The only parameter increased af-
ter BCG-IL-18 treatment compared to BCG treatment or no
treatment was the OVA-speciﬁc IgE after the primary chal-
lenge. These data suggest a systemic transient eﬀect of IL-18
produced by BCG. IL-18 has been shown previously to in-
crease Th2 responses and more particularly IgE production
[13, 29, 30]. The modulation of the production of Th1/Th2
cytokines by IL-18 was suggested to be time-dependent [31],
which might relate to our observation that OVA-speciﬁc IgE
transiently increased due to IL-18 produced by intraperi-
toneally injected BCG. This increase in IgE production was
notaccompaniedbyeﬀectonairwayinﬂammationandfunc-
tion. Dissociation of serum IgE and airway inﬂammation
andhyperresponsivenesswaspreviouslydemonstratedinthe
same model [32]. Conﬂicting data have been reported on
the role of IL-18 in airway inﬂammation. In the presence
of IL-12, IL-18 administered i.p. before the allergen chal-
lenge has been reported to attenuate eosinophil accumula-
tion[14].OVA-sensitizedIL-18deﬁcientmiceexhibitgreater
BAL eosinophilia than wild-type mice [11]. In contrast, local
instillation of recombinant IL-18 was reported to favor the
eosinophil recruitment through the release of eotaxin from
bronchial epithelial cells without any eﬀect on AHR [33].
Moreover,i.p.injectionoflargequantitiesofIL-18,intheab-
sence of IL-12, also increases the recruitment of eosinophils
intheairways[34].Finally,lowerdosesofIL-18regularlyad-
ministered intraperitoneally increase eosinophil recruitment
intheairways3weeksafterthelastinjection[13].BCG-IL-18
administered in our study produces only low doses of IL-18
as previously demonstrated [18] and no IL-18 could be de-
tected in BAL (data not shown). Moreover, BCG has been
shown to favor IL-12 production by macrophages [6]. The
lowdoseofIL-18releasedandthecytokineenvironmentmay
explain the absence of an increased AHR and eosinophilia in
BCG-IL-18-treated mice even after OVA restimulation.
In conclusion, we showed that BCG as well as BCG pro-
ducing IL-18 administered at the time of sensitization pre-
vents airway responses after primary as well as secondary
OVA challenge, suggesting their eﬀect after systemic injec-
tion, which had not been demonstrated yet. Moreover, our
study suggests that, thank to the environment induced by
BCG, low doses of IL-18 do not increase Th2 responses, even
after secondary allergen challenge.
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